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PERBANDINGAN TINDAK BALAS ANTIBODI OLEH KUMPULAN TST+ DAN 
TST- YANG TERDEDAH DALAM JANGKA MASA PANJANG DENGAN 
Mycobacterium tuberculosis 
ABSTRAK 
 
Tuberkulosis (TB) merupakan penyakit yang disebar oleh Mycobacterium 
tuberculosis (MTB) melalui udara. Secara tradisinya T-sel diberikan penekanan yang utama 
dalam pengantaraan jangkitan MTB dengan sedikit penekanan diberikan kepada B-sel dan 
antibodi. Kebolehan untuk menghubungkaitkan kegunaan DNA V dan  tindak balas antibodi 
dalam kedua-dua kumpulan TST+ dan TST- yang sihat yang terdedah kepada MTB dalam 
jangka masa panjang dapat memberi penerangan yang lebih teliti terhadap perlindungan TB 
melalui B-sel dan antibodi. TB sebagai jangkitan melalui udara, sekretori IgA yang hadir 
terutamanya di kawasan mukosa merupakan isotype penting yang akan memberi 
perlindungan berantaraan antibodi. Kumpulan TST- adalah kumpulan yang paling penting 
kerana ia menunjukkan tindak balas T-sel yang lemah bagi ujian TST walaupun selepas 
sepuluh tahun pendedahan kepada TB. Seperti yang dilihat dalam penyakit-penyakit lain, 
toleransi unik terhadap TB dalam kumpul-kumpulan TST mungkin disebabkan oleh 
himpunan antibodi tertentu yang terbentuk akibat penggabungan semula somatik VDJ. Oleh 
yang demikian, kajian penggunaan jujukan DNA V dilakukan untuk mengenal pasti jujukan 
DNA V yang paling kerap digunakan. Keputusannya, jujukan DNA VH3-23 dan VK1 
nenunjuk kekerapan penggunaan yang paling tinggi. Jujukan DNA VH3-23 kemudian 
dianalisasikan oleh penjujukan 454 amplicon untuk memberi permahaman tentang 
penggunaan kegemaran D dan J segmen dan perpasangan D-J. Segmen D3-10 and D3-22 
masing-masing paling banyak digunakan dalam kumpulan TST- dan TST+. Segmen J4 
paling kerap digunakan dalam kedua-dua kumpulan TST. Perpasangan J4 dengan D3-3 
adalah disukai oleh kumpulan TST-. Perbezaan dalam genetik antibodi di antara kumpulan 
mencadangkan kegemaran kumpulan TST- terhadap antibodi yang menpunyai jujukan DNA 
VH3-23, D3-3 dan JH4. Penjujukan 454 hanya mampu menunjukkan kegemaran jujukan 
xiii 
 
DNA antibodi di peringkat genetik tanpa menghubungkaitkan ciri-ciri antibodi di peringkat 
fizikal. Oleh itu, perpustakaan IgA antibodi telah dibina dengan kaedah paparan faj. 
Perpustakaan antibodi ini dapat membentangkan tindak balas antibodi dalam kumpul-
kumpulanTST secara keseluruhan. MTB α-kristal antigen telah dihasil untuk kegunaan 
dalam pemeriksaan biopanning bagi mempelajari tindak balas spesifik antibodi-antigen. 
TST+ E3, C5 and E12 monoklonal domain tunggal telah dikenal pasti dari perpustakaan 
antibodi kumpulan TST+ dan masing-masingnya mengandungi combinasi VH5-D3-9-J4, 
VH1-D1-26-J4 dan VH3-D2-2-J3. Manakala TST- B1, B2, F5 and B8 monoklonal domain 
tunggal telah dikenal pasti dari perpustakaan antibodi kumpulan TST- dan masing-
masingnya mengandungi combinasi VH1-D2-2-J4, VL1-J1, VL2-J3 dan VH4-D4-23-J4. 
Perbandingan dalam penggunanan jujukan DNA V antibodi dan tindak balas spesifik 
antibodi antara kumpulan TST+ dan TST- dapat memberi maklumat yang penting tentang 
mekanisme B-sel dalam MTB imunologi. 
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A COMPARATIVE STUDY OF ANTIBODY RESPONSES IN TST+ AND TST- 
GROUPS WITH LONG TERM EXPOSURE TO Mycobacterium tuberculosis 
ABSTRACT 
 
Tuberculosis (TB) is an air-borne disease caused by Mycobacterium tuberculosis 
(MTB). MTB infection is traditionally conceived as entirely T-cell mediated with little 
emphasis given to B-cell and antibody. The ability to correlate the V gene usage and 
antibody responses in both TST+ and TST- healthy groups that have prolonged exposure to 
MTB can provide deeper insight into the roles of B-cell and antibody in TB protection. As 
TB is an air-transmitted infection, the secretory IgA that exists mainly at mucosal area would 
be the most prominent isotype that might deliver the antibody-mediated protection. The 
TST- group is of particular interest because it shows weak T-cell response for TST test even 
after 10 years exposure to TB. An important potential protection mechanism in the TST 
groups could be due to the specified antibody repertoire shaped by somatic VDJ 
recombination as seen for other diseases. Therefore, V gene usage study was carried out to 
identify differences in usage of V gene segments. As a result, the VH3-23 and VK1 genes 
were shown to be highly used in TST- group. VH3-23 gene was further analysed by 454 
amplicon sequencing to provide an insight into preferential D and J segments usage and D-J 
pairing. D3-10 and D3-22 segments were mostly used in TST- and TST+ groups respectively. 
J4 segment was most highly used in both TST groups. Segment pairing of J4 to D3-3 was 
favoured in the TST- group. The antibodyome difference between the TST groups suggests a 
preference for antibody with VH3-23, D3-3 and J4 gene usage by the TST- group. 454 
sequencing can only show genotypic preference of antibody gene without correlating the 
phenotypic feature of antibody. Hence, IgA scFv library was constructed for TST- and TST+ 
groups by using phage display method. The antibody library will be the representation of 
overall antibody responses of the TST groups. The MTB α-crystalline antigen was generated 
for the use in biopanning screening to study specific antibody response. TST+ E3, C5 and 
E12 single domain monoclonals were identified from TST+ library and were found to use 
xv 
 
VH5-D3-9-J4, VH1-D1-26-J4 with VH3-D2-2-J3 recombination respectively. Whereas TST- 
B1, B2, F5 and B8 single domain monoclonals were identified from TST- group and were 
found to use VH1-D2-2-J4, VL1-J1, VL2-J3 and VH4-D4-23-J4 recombination respectively. 
The V gene usage and specific antibody response comparison between the TST+ and TST- 
groups can therefore provide important insights into B-cell mechanisms in MTB immunity.
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INTRODUCTION 
 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB).  It 
remains as a major public health problem that kills almost 2 million people annually and 
leaves at least one third of the world’s population latently infected. The Bacillus Calmettee-
Guérin (BCG) is the only licensed vaccine against TB, despite widespread coverage, has 
failed to control the spread of TB in high burden areas (Brewer, 2000). 
 
The control of MTB infection in a state of clinical latency indicates the existence of human 
natural immunity against TB. However, the precise immunological components and their 
interactions necessary to control or prevent MTB infection in human remain incompletely 
understood. Although it is established that the cellular immunity mediated by T-cell is 
necessary for the control of latent infection, the presupposition that such immunity is 
sufficient to induce long term protection has recently been challenged. In contrast to the T-
cell response, the B-cell or antibody response is conventionally thought to exert little 
immune control over the course of MTB infection. Until recently, the protective effects in 
mouse challenge models with MTB suggest that specific antibodies may limit the 
dissemination of MTB and could potentially play a role in prevention of MTB infection via 
the mucosal immunity (Maglione and Chan, 2009, Acosta et al., 2013). Furthermore, 
antibodies are now understood to confer protection against a range of intracellular pathogens 
by modulating immunity via Fc-receptor mediated phagocytosis (McEwan et al., 2013, 
Joosten et al., 2013). However, the detail mechanisms involving human B-cell responses 
remain not clear, in particular on the aspect of antibody gene preferences and specific 
antibody response for MTB antigen.  A greater understanding in these unexplored areas may 
provide important insights on how B-cell mechanisms are used for MTB protection. 
 
As TB is an airborne disease, the secretory IgA antibody should be one of the key 
immunological elements to interact with MTB at the mucosal area of the respiratory tract to 
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prevent MTB infection. It has been shown that specific IgA reduces bacterial load in infected 
lungs of mouse models when administered intranasally (López et al., 2009, Reljic et al., 
2006). Using IgA antibodies for immunotherapy of TB is promising with a report of the 
successful use of a novel human IgA monoclonal antibody and IgA purified from human 
colostrum for passive immunotherapy of TB (Balu et al., 2011, Williams et al., 2004, 
Alvarez et al., 2013). Even so, not much is understood about the details of the antibody gene 
diversification process of the IgA isotype with relation to TB. 
 
The adaptive immune system recognizes a vast variety of antigens by its ability to boost a 
diverse repertoire of antibodies. The advances in high throughput sequencing technologies 
has enabled characterization and analysis of large antibody repertoires. This in turn helps to 
provide a proper representation of the abundance of antibodies and their genes that occur in 
the immune system. The antibody repertoire is created by three main genetic modification 
processes, the somatic V-D-J recombination, somatic hypernutation and affinity maturation. 
The patterns of somatic V-D-J rearrangement is principally important in the study of 
antibody variable region gene (V gene) usage. Somatic V-D-J recombination is the earliest 
antibody diversification process that involves random combination of germline V, D and J 
gene segments to generate diverse variable region genes. Ideally, somatic V-D-J is a random 
process. However, if gene segments are preferably used, the resultant antibody repertoire 
will contain a skewed V-D-J number. This gives different immune responses towards 
infections among individuals whereby some individuals exhibit stronger resistance toward 
certain infections and vice versa. Analyses of the use of immunoglobulin V genes in a 
number of studies have revealed a preferential antibody V gene repertoire for patients with 
ankylosing spondylitis (Kim et al., 2010), systemic lupus erythematosus (Kwon et al., 2005), 
chronic lymphocytic leukaemia (Pritsch et al., 1999) and other diseases.  
 
There have been documented cases whereby individuals remain unresponsive to Tuberculin 
Skin Test (TST) despite a high and prolonged exposure to MTB (Rose et al., 1995, Rieder, 
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1999). The interpretation of this phenomenon has been associated more with an intrinsic 
resistance to infection rather than an incapability of reacting to the TST (Rose et al., 1995, 
Cobat et al., 2009). Healthy subjects with more than ten years of exposure to MTB were used 
as study subjects in the present study. The subjects were classified in the TST positive 
(TST+) or TST negative (TST-) group. The TST+ individuals could represent subjects 
susceptible to latent MTB infection but with resistance for progression to clinical TB, 
whereas the persistence of TST negativity in the TST- individuals could be associated with 
resistance to infection, with both populations exhibiting different mechanisms of protection.  
 
To understand the B-cell mechanisms for MTB protection, this project involved systematic 
study of antibody genes on two different levels; the V gene usage level and the specific 
antibody response level. In this study, it was hypothesized that the unique TB tolerance in 
the TST individuals could be due to the specified antibody repertoire shaped by antibody 
diversification process, especially by the somatic V-D-J recombination. Therefore, V gene 
usage study was carried out to compare the usage of 22 different V genes between the TST+ 
and TST- groups. The V gene that was found to be highly used was sent for 454 amplicon 
sequencing to give insights into preferential D and J segments usage and D-J pairing. V gene 
usage study enables identification of genetic determinants that are probably associated with 
resistance to MTB infection. However, it remains unknown whether the genotypic 
preferences seen from the V gene usage study would actually correlate with the generation of 
protective antibodies for TB. Thus, specific antibody response study was carried out and was 
aimed to correlate the antibody genetic preferences seen in somatic V-D-J recombination to 
generation of specific antibodies that are able to bind particular MTB antigen.  
 
The specific antibody response study involved antibody library generation and MTB antigen 
generation. The IgA library was constructed for each the TST+ and TST- group by using 
phage display technology. The concept of phage display was introduced by G. Smith based 
on the ability to express foreign peptides such as antibody fragment as fusion to phage coat 
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protein on the surface of bacteriophage (Cabezas et al., 2008). Phage display technique first 
involves generation of large and diverse antibody library that could mimic the natural 
antibody repertoire of human immune system, followed by isolation of antigen binding 
antibody via biopanning selection. The library represents the overall antibody responses of 
the TST individuals as the antibody genes were derived from the B-cell of the healthy 
subjects. Due to limitations in E. coli folding machinery, only antibody fragments such as 
fragment antigen binding (Fab), single chain fragment variable (scFv) and domain antibody 
are used for phage display library generation (Nelson, 2010). Moreover, the size of full 
antibody is too large to be displayed on bacteriophage. In this study, scFv was used as the 
antibody format for phage display library generation.  
 
Due to its biological and immunological roles in MTB pathogenesis, the MTB α-crystalline 
antigen was generated in this study as a target antigen. The antibody library was screened 
against the MTB α-crystalline antigen for specific antibody-antigen response study with the 
aim to isolate different clones of MTB α-crystalline binding antibodies from each library. As 
phage display allows direct link of phenotypes with the encapsulated antibody genotypes, the 
screening of antibody library thus enables isolation of antibodies with predefined antigen 
specificity. To determine whether or not the antigen specific antibodies contain the genetic 
preferences seen from the V gene usage study, the antibodies retrieved from the biopanning 
selection were sent for DNA sequencing to identify their V, D and J segments usage. The 
isolation of MTB antigen binding antibodies encoded by preferred V-D-J recombination seen 
from the V gene usage study could therefore indicate protective IgA immune responses in 
resistant individuals by promoting the blockage of the entrance of MTB. 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 Tuberculosis  
Tuberculosis (TB) is an air-transmitted disease that causes serious respiratory disability in 
nearly one third of the world population. TB fueled by HIV infection (Law et al., 1996), kills 
millions of people yearly in South East Asia, Africa and other developing countries. Human 
TB infection is mainly caused by Mycobacterium tuberculosis (MTB) via inhalation of MTB 
droplets. MTB was first described by Robert Koch in 1882 (Smith, 1985) who received the 
Nobel Prize in 1905 for this discovery. MTB together with seven closely related 
mycobacterial species that includes M. africanum, M. bovis, M. canetti, M. caprae, M. 
microti, M. mungi, and M. pinnipedii makes up the MTB complex. MTB is a slow growing 
species that divides every 15 to 20 hours (hrs). It is a gram-positive bacterium as its cell wall 
contains peptidoglycans. It is also acid-fast due to the absence of the outer cell membrane. 
The high lipid content in the cell wall especially the mycolic acids (Dubel and ed, 2007) 
plays an important role in MTB virulence and resistance such as determining the 
permeability of the MTB cell surface (Holt et al., 2003).  
 
The clinical symptoms of TB includes chronic cough with blood-stinged sputum, fever, chest 
pain, weight loss, loss of appetite, and night sweat. The environmental exposure to MTB 
does not always result in TB transmission (Nissim et al., 1994). In fact, it is estimated that 
only 20-30% of individuals that have come into contact with someone with active TB 
infection will be infected (Sharma and Mohan, 2013). In most of the infected individuals, the 
disease remains in a latent state where the MTB survives in balance with the immune 
response of the host, with just 5-10% of infection that will eventually lead to primary TB 
infection (Andris-Widhopf et al., 2011). The latent infection might last for the lifespan or 
progress to active TB disease with the risk of 5-10% of infection reactivation (Sripa et al., 
2005). The reactivation of MTB infection is primary due to immunosuppressive medication 
(Summers, 1987) and host genetic factors (Stein, 2011). Most of the active TB infections are 
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pulmonary TB in which the disease develops in the lung of patients. The other minority form 
of the active TB infection (10%) is known as extra-pulmonary TB, in which the infection 
moves from the lung to other organs.  
 
Many diagnostics are available for TB infection. For latent TB diagnosis, the tuberculin skin 
test (TST) is one of the generally use diagnostic tests. TST measures the size of induration 
caused by delayed-type hypersensitivity reaction of the memory T-cell sensitized by prior 
TB infection to the crude mixture of mycobacterial antigens. This TST antigen mixture 
contains the Bacille Calmette–Guérin (BCG) vaccine strains and non-tuberculous 
mycobacterial (Bartu et al., 2008). A more recent diagnostic test for latent TB infection that 
measures interferon Gama (IFN-ϒ) secreted from pre-exposed effector T-cell was 
developed. The T-cell response to the early secretory antigenic target-6 (ESAT-6), culture 
filtrate protein-10 (CFP-10) and TB7.7 MTB specific antigens (Rothel and Andersen, 2005) 
of interferon-ϒ release assay (IGRA) has been reported to give a higher degree of sensitivity 
and specificity (Lalvani, 2007) in low TB burden countries (Dheda et al., 2009). However, 
the use of IGRA assay has been controversial with the variations in gene polymorphism of 
human leukocyte antigen (HLA) (Hang et al., 2011, Duarte et al., 2011) and IFN-ϒ receptor 
(Rosenzweig et al., 2004, Henao et al., 2006, Tso et al., 2005, Hwang et al., 2007) due to 
ethic and/ or geographic distinctions.  
 
1.2 MTB α-crystalline 
Two small heat shock proteins (HSPs), Acr1 (α-crystalline-related protein 1) and Acr2 were 
reported to be highly expressed in MTB under different extreme conditions (Stewart et al., 
2005, Kennaway et al., 2005). Due to its high consistency and contribution to the humoral 
and cellular immune responses, Acr1 (accession number Rv2031c) is a prominent antigen to 
be investigated for its role in MTB infection. This MTB α-crystalline protein is a useful 
antigen with many potential. As a heat shock protein, α-crystalline functions as a molecular 
chaperone that aids assembly and disassembly of protein complexes. The synthesis of α-
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crystalline increases during stressful conditions to protect cells from hostile environment 
(Zügel and Kaufmann, 1999, Kaul and Thippeswamy, 2011). The α-crystalline also involves 
in the formation of an oligomeric structure that prevents aggregation of denatured proteins 
and subsequently aids in the refolding of other chaperones for MTB survival in the adverse 
environment of macrophages (Chang et al., 1996, Siddiqui et al., 2011). More importantly, 
α-crystalline is highly expressed during latency but not in exponential phase (Demissie et al., 
2006). Thus, it is a potential candidate that could facilitate MTB survival during latent 
infection. Due to its biological and immunological roles, MTB α-crystalline could potentially 
be used for early diagnosis, vaccine candidate and for drug development.  
 
1.3 Tuberculosis pathogenesis   
TB pathogenesis is initiated by the entry of MTB to the respiratory route. MTB will travel 
through the mouth or nose to the nasal passage, upper respiratory tract and bronchi to enter 
the lung to encounter the macrophages. Interaction of MTB with macrophages drives the 
innate signaling pathway that leads to the recruitment of the immune cell groups by secretion 
of cytokines and chemokines for early granuloma formation. Neutrophils, natural killer (NK) 
cells and monocytes are among the early leucocytes that are recruited to the site of MTB 
infection. They engulf additional MTB and secrete more cytokines and chemokines. 
Dendritic cells then migrate to the infection site to present the MTB antigens to lymphocytes. 
These signaling events will lead to the hallmark of MTB infection which is the formation of 
granuloma structure (figure 1.3), an immune microenvironment that contains and controls 
the MTB infection (Nissim et al., 1994).  
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Figure 1.3. Structure and cellular components of tuberculous granuloma.  
Macrophages are the principal cell types in granuloma. The differentiated macrophages are 
called epithelioid cells. Macrophages can fuse into giant cells or differentiate into foam cells 
that contain lipid bodies. Other cell types such as B and T-cells, neutrophils, NK cells, 
dendritic cells, fibroblasts and cells that secrete extracellular matrix components also 
constitute the granuloma. The death of the infected macrophages causes the formation of 
necrotic zone, a milky appearance in the center of granuloma with increased number of 
MTB. Figure was taken from (Marks and Marks, 1996). 
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1.4 Tuberculosis immunology 
The immune system consists of both innate and adaptive mechanisms for recognition and 
elimination of pathogen. Early TB exposure is mediated by innate immunity, an antigen-
nonspecific defense that host uses immediately after exposure to an antigen (Bradbury et al., 
2003). As long as the infection is kept constant within the granuloma by adaptive immunity, 
TB infection will remain latent. Conversely, decline in the adaptive mechanism will lead to 
the failure of granuloma containment, followed by effective MTB replication, development 
of secondary TB disease and disease transmission to other individual (Schier et al., 1996).  
 
Adaptive immunity in vertebrates such as humans has evolved to include both the cellular 
and humoral components. The cellular immunity is mediated by T-cells that target and kill 
infected cells directly or through activation of cytokines (Chowdhury and Pastan, 1999). 
Whereas the humoral immunity is mediated by B-cells that generate antibodies against a 
specific antigen (Hoogenboom, 1997). B-cell also helps in pathogen clearance by acting as 
antigen presenting cells (APCs), activating the complement system and immune cells such as 
neutrophils, NK cells and macrophages via antibody-dependent cell mediated cytotoxicity 
(ADCC) (Schier et al., 1996, Sheedy et al., 2007, Yang et al., 1995). The protection against 
intracellular pathogen such as MTB is generalized as entirely T-cell mediated; whereas B-
cell and antibodies are perceived only for extracellular infections (Sripa et al., 2005). This 
follows the concept that antibodies which circularize through the serum, are dedicated for 
extracellular microbes. In contrast, the T-cell that only response to processed antigen can 
look within the cells and eliminate intracellular pathogens (Pansri et al., 2009). Therefore the 
T-cells and T-cell receptor (Casetti et al., 2008, Mahon et al., 2012, Plosker and Figgitt, 
2003, Qiao et al., 2011) studies for MTB have been extensively illustrated with little 
emphasis given to B-cells and antibodies.  
 
However, the idea of the immunological duality whereby intracellular infection is conferred 
by cellular immunity and extracellular infection is conferred by humoral immunity is 
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problematic. Studies have shown that priming of the humoral immunity is effective to 
prevent intracellular pathogen infection. For instance, viral infections such as influenza 
(Miller et al., 2005), measles (Cabezas et al., 2008) and varicella (Almquist et al., 2006) have 
shown to be significantly reduced or entirely eliminated after administration of antibody-
based vaccine. This long term immunity against the viral pathogens is suggested to be 
mediated by the neutralizing antibodies that can prevent viral cellular entry and molecular 
interactions (Fermer et al., 2004). Other than viral infections, humoral response against 
intracellular bacteria and parasite infections such as MTB (Kay et al., 1996), Plasmodium 
chabaudi (Valjakka et al., 2002), and Pneumocystis carinii (Wu et al., 2004) were also 
demonstrated in B cell deficient mice studies. As such, the adaptive immunity is probably a 
more resourceful system that includes both the cellular and humoral responses to achieve 
maximally collaborative, operative, and versatile controls for pathogenic infection (Maglione 
and Chan, 2009). An example is the conjugate Haemophilus influenzae type b vaccine that 
combines the T-cell independent carbohydrate antigen with a T-cell dependent protein 
immunogen to induce long-term antibody immunity in young children (Hoogenboom, 1997, 
Schier et al., 1996). Another possible mechanism is by modulation of T-cell activation 
processes through generation of antibodies and cytokines, which can either improve or 
inhibit T-cell responses (Lund, 2008, Youinou et al., 2009, Winer et al., 2011, Fillatreau, 
2012). Emerging evidences have also proposed the involvement of B-cell in priming 
memory T-cell immunity (Kennaway et al., 2005, Zügel and Kaufmann, 1999, Kaul and 
Thippeswamy, 2011). 
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1.5 Antibody basic structure  
The recognition protein found in the serum and other body fluids that reacts specifically to 
an antigen is called an antibody (ab) or immunoglobulin (Ig). A host can produce a vast array 
of antibodies that are structurally similar (Y-shaped molecules) yet unique in term of 
specificity. The major contribution of B-cell for humoral immunity is the production of 
antibodies. The basic antibody structure is shown in figure 1.5. Generally, the difference in 
amino acids in the arms of an antibody confers its specificity towards an antigen. Whereas 
the base stem of an antibody is responsible for the biological activity of the antibody by 
recruiting immune cells and cytokines to eliminate pathogen.  
 
Generally, each antibody consists of two light chains and two heavy chains. Each light chain 
pairs with a heavy chain, and each heavy chain pairs with another heavy chain by inter-chain 
disulfide bonds and non-covalent interactions. The two light chains (23 kDa each) and two 
heavy chains (50 kDa each) are identical. Each chain is divided to two regions, the variable 
(V) and constant (C) regions. The amino terminal contains the V region while the carboxyl 
terminal contains the C region. Variability of the amino acid sequences is localized within 
certain sections of the V region, and these sections have extensive sequence variation from 
antibody to antibody. These sections are called complementarity determining regions 
(CDRs). Moving from the amino terminal, the three CDRs are called CDR1, CDR2 and 
CDR3. When the light and heavy chains are joined, the CDRs will form a cleft that serves as 
the antigen-binding site. The amino acid sequences of the CDRs determine the shape and 
ionic properties of the antigen-binding site therefore directly defining the antibody 
specificity. Intervening sequences between the CDRs have restricted amino acid variability. 
These invariant segments constitute the four framework (FR) regions, which are called FR1, 
FR2, FR3 and FR4, and define the location of CDR. Both the light chain and heavy chain 
consist of multiple variable (V), numerous diversity (D) (for heavy chain only), several 
joining (J) gene segments and some constant region (C) exons (for heavy chain gene only). 
The Vκ and Vλ gene segments contain FR1, FR2, and FR3, CDR1, CDR2 and the amino  
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Figure 1.5. Basic IgG antibody structure.  
 
IgG composes two identical heavy and light chains joined by disulfide bonds. Each chain has 
a variable (V) region that contributes to the antigen binding site, and a constant (C) region 
that determines the effector properties. The flexible Fab movement is due to the hinge region 
that joins the arms and the stem portion. Different antibody isotypes have different Fc 
fragment and thus different biological properties. 
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terminal portion of CDR3. The Jκ and Jλ gene segments contain the carboxyl terminal of 
CDR3 and FR4. For VH gene segments, it contains FR1, FR2, FR3, CDR1, CDR2 and the 
amino terminal portion of CDR3. The DH gene segment contains the middle portion of 
CDR3, and the JH gene segment contains the carboxyl terminal of CDR3 and FR4 (Wang et 
al., 2005). The constant regions for both the λ and κ light chain genes are encoded as single 
exon. In contrast, the heavy chain gene contains exons that encode different constant regions 
for production of antibodies with different classes and subclasses (Choi et al., 2006).  
 
The antibody stem region that engages biological functions such as activation of complement 
system, enhanced phagocytosis and ADCC is termed as fragment crystallizable (Fc) region. 
The IgG, IgA and IgD antibodies have a C region for each light chain and three C regions 
(CH1, CH2, and CH3) for each heavy chain. The IgM and IgE antibodies have an additional 
CH4 domain. The CH1 domain is located within the fragment antibody (Fab), whereas the 
remaining CH domains comprise the Fc region that defines the isotype of antibody. The 
heavy chain V region shows similarity to the V region of the light chain, while the three C-
region units show strong homology to each other and to the C region of the light chain. 
Antibodies also demonstrate segmental flexibility, in which the two Fab portions can move 
relative to one another on antigen binding. The angle varies from 60 to 180 degrees. This 
flexible region is called hinge region and is located between the CH1 and CH2 domains. Only 
Ig G, Ig A and Ig D antibodies molecules have the hinge regions. 
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1.6 Antibody diversity creation 
An enormous antibody repertoire must present in host to counteract with large diverse 
antigen that occurs naturally. Three genetic modification processes known as VDJ 
recombination, somatic hypermutation, and affinity maturation are responsible for the 
creation of antibody diversity. The earliest antibody diversification process is known as VDJ 
recombination that occurs at the pro-/pre-B-cell stage in which the recombinase enzyme 
complex catalyzes the fusion of one of the DH gene to a JH gene with the removal of the 
intervening DNA sequences (Boder et al., 2000). The recombinase then joins one of the VH 
genes to the rearranged DHJH gene. Terminal deoxynucleotidyl transferase (TdT) is 
expressed to increase the amino acid diversity of the rearranged VHDHJH gene by random 
addition of nucleotides into the DH-JH and VH-DHJH joining sites. If VHDHJH rearrangement 
produces an in frame and functional heavy chain transcript, an IgM heavy chain will be 
synthesized and paired with the surrogate light chain heterodimer (λ5 and VpreB proteins). 
Allelic exclusion is a process of expression of this pre-B-cell receptor in order to prevent VH 
to DHJH rearrangement on other chromosome, so that each B-cell has one unique specificity 
for an antigen. Once a functional heavy chain is generated, B-cell down regulates its TdT 
gene and initiates light chain rearrangement. Firstly, a Vκ gene segment fuses with a Jκ gene 
segment. If κ light chain assembly is successful, the κ light chain pairs with the heavy chain 
to form a functional IgM receptor on the naive B-cell surface. The rearrangement of the λ 
light chain proceeds if the κ rearrangement is unsuccessful (Choi et al., 2006).  
 
Immature B-cell extends transcription of the heavy chain locus to include the exons encoding 
the Cδ chain for production of IgD that is downstream of exons encoding Cµ chain. IgM and 
IgD are co-expressed by alternative RNA splicing of the VHDHJH exon to either the µ or δ 
exons. IgM and IgD on each of the newly mature B-cell share the same variable domains, 
thus have the same antigenic specificity. Mature IgM+IgD+ B-cell leaves bone marrow to 
enter the blood and migrate to the peripheral lymphoid tissues to encounter antigen. The fate 
and lifespan of mature B-cell are depend on antigen selection. Unstimulated B-cell lives for 
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short period, usually several days or few weeks. If B-cell is activated in the absence of T 
helper cells and without the assistance of T-cell costimulatory proteins, B-cell will 
differentiate into short-lived plasma cells with little B-cell memory (Wang et al., 2005). T-
cell dependent stimulation usually occurs in the germinal center to increase the antibody 
gene diversification, including somatic hypermutation at the variable regions that leads to 
affinity maturation and class-switching (figure 1.6.1) in which T-cell cytokines control the 
antibody isotype produced (Larentis et al., 2011a). Unswitched B-cell retain the IgM and 
IgD expression. B-cell that undergone class switching and lost IgM and IgD expression is 
called switched memory B-cell (Larentis et al., 2012). Memory responses are characterized 
by faster production of high affinity IgG, IgA or IgE antibodies after subsequent exposure to 
the same antigen. Memory B-cell can be subsequently activated to become long-lived plasma 
cells (Boder et al., 2000). The B-cell differentiation and development is summarized in 
figure 1.6.2. 
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Figure 1.6.1. Somatic VDJ recombination and class-switch recombination.  
 
Heavy chain variable domain is assembled from V, D, and J gene segments through VDJ 
recombination. It involves cleavage of the DNA sequences in the recombination signal by 
the recombination-activating gene 1 (RAG1)–RAG2 complex. Joining of the DNA breaks 
requires non-homologous end-joining (NHEJ) proteins, including Ku70, Ku80, ARTEMIS, 
X-ray repair cross-complementing protein 4 (XRCC4), DNA ligase IV and the catalytic 
subunit of DNA-dependent protein kinase (DNA-PKcs). Transcription is driven by a 
promoter upstream of the rearranged VDJ segment (blue arrow) to facilitate the synthesis of 
a µ heavy chain. Folowed by association with a light chain, an IgM is formed on the B-cell 
surface. Secondary isotypes are then produced by class-switch recombination (CSR) to 
exchange the constant region of the heavy chain with a set of downstream constant-region 
genes (CSR to IgE is shown). This deletional-recombination reaction requires the enzyme 
activation-induced cytidine deaminase (AID) to generate DNA breaks at switch (S) regions 
(located at downstream of the constant region genes), followed by DNA repair. This leads to 
a rearranged CH locus and deletion of the intervening sequence as an episomal circle. 
Cytokines stimulate transcription (red arrows) through the CH gene and determine the 
antibody isotype that the B-cell will switch to. The rearranged variable regions of both the 
heavy and light chains also undergo a high rate of point mutation through the process of 
somatic hypermutation (SHM) (not shown). The Emu and 3'-regulatory-region (3' RR) 
enhancers influence V(D)J recombination and CSR respectively. Figure was taken from 
(Einsfeldt et al., 2011). 
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Figure 1.6.2. B-cell development and antibody diversification.  
 
During antigen-independent B-cell development in the bone marrow, heavy chain gene 
rearrangement occurs first followed by light chain. The naïve B-cell expresses fully formed 
IgM and IgD receptors on the surface and leave the bone marrow. In peripheral lymphoid 
tissues, B-cell matures further under the influence of antigen and T-cell to undergo isotype 
switching and affinity maturation through somatic mutation. Activated B-cell enter follicles 
and establish germinal centers to form memory B-cell. Memory B-cell can be activated to 
become long-lived plasma cells in the future. Patients with X-linked agammaglobulinea 
(XLA) have difficulty to produce IgM and immature B-cell. Patients with hyper-IgM 
syndrome (Hyper IgM) cannot undergo class-switching process. Patients with selective IgA 
deficiency (IgAD) or common variable immune deficiency (CVID) can undergo class switch 
recombination but have problem to become memory B-cell or plasma cells. Figure was taken 
from (Wang et al., 2005). 
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1.7 Antibody isotypes 
During early B-cell development, IgM and IgD are co-expressed on B-cell surface. During 
antigen stimulation and also cytokine regulation, the VDJ unit of the IgM and IgD can be 
associated with other isotype. This enables the antibody production with different Fc region 
(IgG, IgA and IgE) but the same antigenic specificity (same VDJ unit). There are five main 
classes of antibodies, the IgM, IgD, IgG1-4, IgA1-2 and IgE. The isotypes differ in many 
properties, such as size, structure, location, Fc binding and response to antigen.  
 
IgM is the first antibody expressed on the B-cell surface. On maturation and antigen 
stimulation, B-cell secretes pentameric IgM with high avidity. Early expression during B-cell 
development allows IgM to act as natural antibody to eliminate pathogen during early 
infection before presence of sufficient amount of IgG to mediate of primary antibody 
response (Gronwall et al., 2012). IgD, similar with IgM, is expressed as antigen receptor on 
naïve B-cell surface. Circulating IgD is present at very low serum levels with short serum 
half-life (Vladutiu, 2000). As it is not known to participate in major antibody effector 
mechanisms, the fuction of circulating IgD is still unclear. IgG is the predominant antibody 
isotype and has the longest serum half-life. It confers the major antibody-based immunity 
against pathogen, including complement fixation, opsonisation and neutralization of toxins 
and viruses. IgG is the only antibody isotype that can cross placenta to give passise 
immunity to the fetus (Palmeira et al., 2012). Although IgE is found at the lowest serum 
concentration and has the shortest serum half-life, it is a very powerful antibody. It is 
associated with hypersensitivity and allergic reactions by binding to the FcɛRIs on mast 
cells, eosinophils, Langerhans cells and basophils to trigger release of histamine. IgE also 
involves in protection against parasitic worms (Galli and Tsai, 2012).  
 
IgA is found mainly in mucosal areas such as respiratory tract, gut and urogenital tract; and 
also in secreations including saliva, breast milk and tears. The serum level of IgA is higher 
than IgM but lower than IgG. However, IgA level is much higher than IgG at mucosal 
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surfaces and in secreations. IgA generally appears as monomer structure in the serum. When 
presents at mucosa, the IgA is termed as secretory IgA (sIgA)  in a dimer structure that is 
accossicated with a J-chain and another polypeptide chain known as secretory component 
(SC). The transport of polymeric IgA (pIgA) within mucosal lymphoid tissue into mucosal 
secretion is through polymeric immunoglobulin receptor (pIgR). Dimeric IgA with the J-
chain is bound by the pIgR on basolateral surface of lymphoid epithelial cells. Receptor-
mediated endocytosis facilitates the transport of dimeric IgA through epithelial cell 
cytoplasm. The extracellular portion of the pIgR is cleaved to form the SC and covalently 
binds with the pIgA by disulfide bond. This complex of  dimeric IgA with SC forms sIgA. 
IgA has critical role in protecting mucosal areas from toxins, bacteria and viruses by direct 
neutralization or prevention of pathogen binding to the mucosal surfaces. It is suggested that 
sIgA might act as potentiator of the immune response in intestinal tissue by mean by 
uptaking antigen to dendritic cells (Chew et al., 2012).  
 
1.8 High throughput antibody sequencing  
Antibody diversity is created by several mechanisms. The most fundamental one is through 
somatic VDJ recombination. There are 56 V, 23 D and 6 J gene segments identified in 
human genome (Sunitha et al., 2000). The antibody diversity is mostly focused at the site of 
a heavy chain VDJ gene ligation called CDR-H3. Due to the combinatorial and junctional 
modification mechanisms that generate CDR-H3, it is the most diverse component in terms 
of amino acid length and sequence and is the main determinant for antigen specificity 
(McBride et al., 2005, Nikerel et al., 2006, Ko et al., 2009). Comprehensive desriptions of 
the CDR-H3 diversity, VDJ recombination and B-cell maturation in response to infection 
may greatly enhance clinical diagnostic, antibody therapeutic and vaccine design.  
 
Advance in sequencing has enabled valuable insights and provided a broader picture on the 
genetic basis of antibody repertoire. Recent studies used high throughput sequencing to 
describe antibody diversity in human (Félix et al., 2011, Lessa-Aquino et al., 2013, Arnaout 
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et al., 2011, Nabity et al., 2012) and zebra fish (Weinstein et al., 2009). The main purpose of 
high throughput sequencing is to explore the antibodyome (Lin et al., 2009) so that the 
antibodies expressed by different subset of B-cell in particular those that are elicited by 
antigen stimulation can be identified for functional characterization. Analyses of the Vκ, Vλ 
and VH gene usage and recombination frequencies between particular V-J, V-D and D-J gene 
segment pairing in the antibody repertoire of healthy individuals (Arnaout et al., 2011, Lin et 
al., 2010), individuals with specific infection (Wu et al., 2011, Donovan et al., 1996, Larentis 
et al., 2011b), autoimmune diseases (Silva et al., 2007, Frachon et al., 2006) as well as in 
antibody maturation process in zebrafish (Ramos et al., 2004) have revealved remarkable 
skewings and variabilities that may in turn shapes the repertoire in the antigen-exposed B-
cell and results in different immune responses among individuals.  
 
Eperimental design for high throughput antibody sequencing involves several parameters 
(figure 1.8.1). The first consideration is the source of B-cell. Most studies have used B-cells 
from peripheral blood as it is readily accessible. The second consideration is to use either 
genomic DNA (gDNA) or mesenger RNA (mRNA) as template. Sequencing of both gDNA 
and mRNA enables estimation of the B-cell clonality (number of B-cell expressing a given 
antibody sequence), as the number of sequence read is usually proportional to the number of 
gene if no primer bias. The gDNA amplification commonly uses PCR primers that are 
complementary to the rearranged VDJ recombinants. The mRNA amplification is far more 
easier for rearranged V genes as the introns are removed by splicing. After reverse 
transcription of mRNA to cDNA, cDNA amplification can be performed either by using a 5’ 
primer pool complementary to the FR1 of the V genes and a single 3’ CH1 (or Cκ/Cλ for light 
chain genes amplification) or alternatively by using the 5’ rapid amplification of cDNA end 
(RACE) technique (Ozawa et al., 2006). The amplified sequences can then be sequenced by 
using suitable platform, depending on desired application and technology compatibility. 
